During a recent press conference, the CEO of Novo Nordisk addressed concerns regarding compounded semaglutide and its potential impact on public health in the United States. Semaglutide is a medication used to treat type 2 diabetes and obesity, and the company has been at the forefront of developing innovative treatments in this field.
The CEO highlighted the dangers associated with compounded versions of semaglutide, emphasizing that these products may not meet the same safety and efficacy standards as the company's FDA-approved formulations. Compounded medications are custom-made by pharmacists to meet specific patient needs, but they are not subject to the same rigorous testing and oversight as commercially available drugs.
